Floatz logo

Efanesoctocog Alfa

Hemophilia A, Severe

Swedish Orphan Biovitrumprotein_peptidePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Hemophilia A, Severe cohort.

Asset / SponsorPhaseRating
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
AryoGen Pharmed Co.
Phase 4BBB
Human-Cl Rhfviii
Octapharma
Phase 3BBB
Emicizumab
Chulalongkorn University
Phase 4BBB
Rfviiifc
Bioverativ Therapeutics Inc.
Phase 3BB
Alphanate Sd/Ht
Grifols Biologicals, LLC
Phase 4BB

View all 21 →

Same molecule, other indications

Efanesoctocog Alfa is also rated in:

hemophilia ADormant
BBB
Indicative ·
72 / 100
View asset →
hemophiliaDormant
BB
Indicative ·
65 / 100
View asset →
synovitisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →